Sergio A. Giralt, MD, discusses how the approval of axatilimab and emerging therapies, including ibrutinib and rituximab combinations, are reshaping the treatment landscape for chronic graft-vs-host disease (cGVHD), with a focus on improving efficacy, safety, and patient outcomes based on recent American Society of Hematology Annual Meeting and Exposition (ASH 2024) findings.